DNLI Denali Therapeutics Inc.
DNLI Denali Therapeutics Inc.
Healthcare · Biotechnology
Desk view
Market read
POC $20.24 · VWAP $20.36 · -13.5% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster Director, Officer + 1 other sold $363.7K, Sep 3–9
Coverage
1 watchlist
DNLI Price Structure
Loading timeframes…
Peers
Every watchlist DNLI belongs to, members best 30-day change first — DNLI highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: revenue $4M, diluted EPS -$0.68, net income -$128M (SEC filing). Across the print the stock moved +1.7% (close before → first close after).
full note →Against street estimates
How DNLI's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about DNLI from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 3 days ago · Oct 14
- User | chroniclejournal.com - Denali Therapeutics Inc. - Common Stock (Nasdaq:DNLI) Stock Quote
- Markets & Stocks - Denali Therapeutics Inc. - Common Stock (Nasdaq:DNLI) Stock Quote
- PRN_FinancialWrapper | PR Newswire - Denali Therapeutics Inc. - Common Stock (Nasdaq:DNLI) Detailed Stock Data
- Denali Therapeutics (DNLI) Q2 2026 Earnings Results & Call ...
- Denali Therapeutics Share Price Today | NASDAQ: DNLI - Investing.com IN
DNLI research tape
24 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.